* Cutting-edge AI/machine learning technology with validation in humans for
early diagnosis of lung cancer
* In silico detection for 12 additional cancers, including pancreatic
* More than 2,600 proprietary biomarker panels
* Rapidly expanding to other cancers and diseases
* Innovative biotechnology firm with promising pancreatic cancer results
projected to begin human studies for several challenging solid tumors by
mid-2024
* Combination creates potential multiplier effect to accelerate earlier
diagnosis, more effective therapy, and precision, in silico drug discovery
LOS ANGELES, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Renovaro BioSciences Inc.
(NASDAQ:RENB) (formerly NASDAQ: ENOB), an advanced, pre-clinical biotechnology
firm in cell, gene and immunotherapy focused on solid tumors with short life
expectancy, has executed a binding, exclusive letter of intent to merge a
subsidiary with the cutting-edge health AI company GEDi Cube Intl Ltd. The
combined company would aim to accelerate diagnosis, enhance treatment
effectiveness, discover new therapies, and expand access to life-saving
technologies for cancer and other diseases.
"I have been privileged to lead life sciences groups at Intel, Oracle, and most
recently, NVIDIA," said Craig Rhodes, CEO of GEDi Cube International Ltd.
"But GEDi Cube's remarkably innovative technology developed over nearly a
decade has already validated earlier diagnoses of lung cancer in humans at a
leading university hospital and created the technology for 12 additional
cancers, including pancreatic and breast cancer, which is very inspiring and
exciting."
"We are rapidly expanding our technologies to include other cancers and
diseases," Rhodes added. "I believe that uniting with Renovaro BioSciences'
potential solid tumor therapies is not merely synergistic. It could also create
a multiplier effect to expedite diagnosis, improve treatment outcomes and
discover, in silico, new therapies to improve many lives."
"Renovaro, Latin for 'renewal,' represents our company's mission," Renovaro
Biosciences CEO Dr. Mark Dybul said. "Our advanced cell, gene and immunotherapy
techniques are designed to reinvigorate the body's natural tumor-fighting
mechanisms. I believe joining forces with GEDi Cube could enhance the efficacy
of our upcoming trials and speed up the discovery of novel treatment approaches,
thereby extending our life-saving technology to more cancer patients
and renewing hope for them and their families," Dr. Dybul added.
While Renovaro's current results focus on pancreatic cancer, it plans to include
other solid tumors with short life-expectancy in the first in human Phase I/IIa
studies that are in track to start by mid-2024. The rates of these cancers and
other serious health conditions are rising rapidly as many populations are
growing older. As a concrete example of a potential multiplier effect, GEDi
Cube's AI technology could potentially enable the combined Company to focus
upcoming human trials on the cancers most likely to respond to therapy, expand
the database of key markers for earlier diagnosis and disease progression and
discover new generations of Renovaro's treatment approach as well as entirely
new therapies.
Dr. Anahid Jewett is a leading cancer immunotherapy researcher at UCLA who has
conducted independent, pivotal studies with Renovaro's technology in different
animal models. She has consistently demonstrated 80% to 90% pancreatic tumor
reduction in size and weight that was correlated with significant enhancement of
key aspects of the immune response. "After decades as a scientist searching for
the best ways to translate laboratory studies into life-saving treatments, I am
very excited about the possibilities of uniting advanced AI with some of the
most promising results we have seen in our pancreatic cancer models with
Renovaro's technology," Dr. Jewett said. "To me, this is the future of
medicine."
FORWARD-LOOKING STATEMENT
Statements in this press release that are not strictly historical in nature are
forward-looking statements. These statements are only predictions based on
current information and expectations and involve a number of risks and
uncertainties, including but not limited to the success or efficacy of our
pipeline. All statements other than historical facts are forward-looking
statements, which can be identified by the use of forward-looking terminology
such as "believes," "plans," "expects," "aims," "intends," "potential," or
similar expressions. Actual events or results may differ materially from those
projected in any of such statements due to various uncertainties, including as
set forth in Renovaro BioSciences Inc. (NASDAQ: RENB) most recent Annual Report
on Form 10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
hereof. All forward-looking statements are qualified in their entirety by this
cautionary statement, and Renovaro Biosciences, Inc. undertakes no obligation to
revise or update this shareholder letter to reflect events or circumstances
after the date hereof.
For more information on Renovaro Biosciences Inc. go to their website at
www.renovarobio.com (http://www.renovarobio.com).
For more information on GEDi Cube Intl LTD, go to their website at
www.gedicube.com (http://www.gedicube.com).
Source: Renovaro Biosciences
Press Contact: IR@Renovarobio.com (mailto:IR@Renovarobio.com)
IR@Gedicube.com (mailto:IR@Gedicube.com)
Â